title: Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials.
abstract: The ethinylestradiol 20 microg/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being, consistent with other drospirenone-containing COCs. In clinical studies, >85% of those who received the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC were satisfied or very satisfied with this contraceptive. The positive attributes of the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC beyond contraceptive protection may have important implications for improving treatment compliance and reducing treatment discontinuation. Physical well-being stayed the same or improved during use of this COC in 56% and 34% of women, respectively. Emotional well-being stayed the same or improved in 71% and 20% of women, respectively.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Basel, Basel, Switzerland. jbitzer@uhbs.ch
authors.forename: Johannes
authors.initials: J
authors.lastname: Bitzer
authors.forename: Anna M
authors.initials: AM
authors.lastname: Paoletti
mesh_terms: D000736:Androstenes / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D010349:Patient Compliance; D017060:Patient Satisfaction; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016387:Women's Health
chemical_list: D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; C534342:drospirenone and ethinyl estradiol combination; D004997:Ethinyl Estradiol